chevron_leftBack
As of 14 June 2026, Wuhan Hvsen Biotechnology Co.,Ltd. has a market cap of $793.62M USD, ranking #12112 globally and #3566 in China.
It ranks #1100 in the Healthcare sector, and #205 in the Biotechnology industry.
Key Stats
Market Cap
$793.62MUSD
5.38B CNY
Enterprise Value
$756.97MUSD
5.12B CNY
Revenue (TTM)
$256.85MUSD
1.74B CNY
EBITDA (TTM)
$65.74MUSD
444.86M CNY
Net Income (TTM)
$42.26MUSD
286.33M CNY
EBITDA Margin
26%
Profit Margin
16%
PE Ratio
18.8
Forward PE
23.6
PS Ratio
3.1
PB Ratio
2.4
EV/EBITDA
11.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jie Han
open_in_new
Employees
1,028
Founded
2002
Website
whhsyy.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.4% | -3.1% | 9.8% | -8.1% | 17% | 19% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
300871
武汉回盛生物科技股份有限公司 Class A
ISIN: CNE1000047H6
Shares Out.:
Shares Outstanding:
201.03M1
Shares Float:
110.889M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
26.28 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Wuhan Hvsen Biotechnology Co.,Ltd.
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SHEK: 2269
|
$17.44B
2K%
136.71B HKD
|
25.3
|
|
SHEK: 1093
|
$12.2B
1K%
95.58B HKD
|
22.1
|
|
SHE: 002422
|
$8.0B
909%
54.23B CNY
|
34.4
|
|
|
$7.33B
824%
49.69B CNY
|
-
|
||
SHEK: 1530
|
$7.08B
792%
55.5B HKD
|
5.8
|
|
SHE: 300347
|
$6.72B
747%
45.52B CNY
|
61.6
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
23K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
20K%
|
19.0
|
|
EBR: ARGX
|
$47.84B
6K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
6K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
5K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
5K%
33.71B CHF
|
37.2
|
chevron_leftBack